CD226 and neoplasm: Moreover, their profile is marked by the expression of several activating receptors KLRD1 (CD94), KLRF1, CD226 (DNAM1), and NKG7. On the other hand, the predominant tumor-associated NKs display low cytolytic potential, along with the expression of the inhibitory receptor KLRC1 (NKG2A).